GeroScience review evaluates non-surgical therapies and genicular artery embolization for preserving knee joint healthspan

A geroscience-guided review in GeroScience advocates for a shift from mechanical paradigms to phenotype-informed osteoarthritis therapies, highlighting that recent sham-controlled data fail to show consistent efficacy for emerging interventional procedures.

A narrative review published in GeroScience evaluated clinical evidence from January 2010 to May 2026 regarding non-surgical therapies for knee osteoarthritis (KOA) within a geroscience and phenotype-informed framework.

The authors synthesized evidence on lifestyle interventions, intra-articular therapies, genicular nerve ablation (GNA), and genicular artery embolization (GAE).

While core conservative interventions (weight reduction and exercise) received strong guideline support, therapies like hyaluronic acid and platelet-rich plasma (PRP) remain limited by heterogeneous clinical data.

The review noted that GAE is biologically plausible for synovitis/hypervascularity-dominant KOA, but high-quality sham-comparator trials do not yet establish reproducible, statistically significant superiority over placebo.

Osteoarthritis is increasingly characterized as an age-associated degenerative disorder driven by cellular senescence, inflammaging, and vascular remodeling, rather than a localized mechanical failure.

The failure of early senolytic trials like UBX0101 to demonstrate clinical symptomatic benefit underscores the difficulty of translating target-specific biological mechanisms into patient-reported outcomes.

Symptom modulators are frequently conflated with true structure-modifying therapies; the authors propose a clinical trial framework that separates temporary pain reduction from the biological preservation of joint healthspan.

Developers of novel knee osteoarthritis therapeutics face severe translational hurdles due to high placebo response rates, which have historically undermined both invasive procedures (such as GAE) and localized biologic injections.

The lack of standardized patient selection criteria for clinical trials of regenerative approaches, such as mesenchymal stromal cells, continues to delay regulatory pathways and commercial adoption.

The market is expected to demand phenotype-stratified trial designs that utilize validated imaging and molecular biomarkers to enrich for specific disease pathways, such as synovitis-dominant versus mechanical-dominant KOA.

The initiation of phenotype-stratified trials incorporating artificial intelligence, radiomics, and magnetic resonance imaging (MRI) markers to prospectively identify patients most likely to respond to vascular or biological interventions.

The standardization of patient-enrichment criteria for GAE trials, focusing on MRI synovitis scores and Doppler vascular grading to measure true structural and physiological joint-aging endpoints.